Biopharmaceutical Research Firm, WCCT Global, Acquires New Talent to Support Expansion and Launches Pain Model

WCCT Global expands their early stage drug evaluation capabilities and its late phase dose response offerings.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Cypress, California, Costa Mesa, California and Langhorne, Pennsylvania (PRWEB) December 12, 2012

WCCT Global, LLC, a contract research organization (CRO) supporting Phase I - IV biopharmaceutical and device development, today announced its appointment of Ms. Linda Gozar, MPH, CCRC as Director of Outpatient Research to expand WCCT’s early stage drug evaluation capabilities and its late phase dose response offerings.

WCCT Global- Early Phase specializes in complex Phase I-IIa special population studies, which assess a drug’s activity and safety within a particular subset of a larger population. The company has extensive expertise in protocol design, volunteer enrollment, and management of ethno-bridging, thorough QTc (important cardiac safety parameter), respiratory, infectious disease (vaccine & HCV), pediatric, post-menopausal and renal trials. WCCT Global –Late Phase CRO specializes in Phase II to IV full service single/multiple center trials.

Ms. Linda Gozar, MPH, CCRC
Ms. Gozar is a dynamic clinical operations expert with a proven track record guiding projects from concept development through execution. With over 12 years of late phase clinical trial experience, she has screened and enrolled 1000+ subjects for late stage clinical trials. Prior to joining WCCT Global, she held a similar leadership position. Her areas of therapeutic expertise include vaccines, podiatry pain models, women’s health, respiratory, and gastrointestinal diseases.

Chief Operating Officer Jon Rojas said, “We are thrilled to have Linda join our management team and heading our late phase expansion initiative. Her extensive experience project managing late phase trials, particularly vaccine and analgesia trials, will allow us to take our late phase operation to the next step.”

About the bunionectomy pain model:
Bunionectomy surgery has been used as a model of postoperative pain to support analgesic drug development decisions for several years. The pain consistency and intensity following this ambulatory surgical procedure has been proven adequate to predict analgesic activity (onset and duration) in a relatively small number of subjects. This model has also been able to detect analgesic activity of compounds with diverse pharmacokinetic profiles and mechanisms of action. WCCT Global is proud to announce that it can now provide this additional service to its Pharma development partners.

About WCCT Global
WCCT Global is a global provider of outsourced early drug development services to the pharmaceutical, biotechnology and medical device industries. As a drug development partner, WCCT Global partners with domestic and foreign innovator companies who need regulatory, program management, and strategic consulting support from First-in-Man thru the proof of concept stage with an emphasis on overseeing and executing on trials in special disease populations, ethnobridging volunteers, and cardiac safety studies. Visit WCCT Global on the web and if you would like further information on how WCCT Global can be of service to you,click here..
WCCT Global Website: http://www.wcct.com


Contact

  • Matt Miller
    WCCT Global, LLC
    1.866.429.9228 2029
    Email
Follow us on: Contact's Facebook